Dear WIPO Re:Search Members and Friends,

We are pleased to share the 2018 BVGH Partnership Hub Annual Report. In these pages we celebrate the expansion of the WIPO Re:Search portfolio to 140 R&D collaborations focused on improving the prevention, diagnosis, and treatment of some of the world’s most devastating diseases, and the growth of our membership to over 140 organizations across 40 countries. We look forward to building on these successes and continuing to drive product development for the most pressing global health needs.

In honor of International Women’s Day, we also celebrate the Consortium’s achievements in empowering female researchers across the globe and promoting the advancement of women in science. Women account for a minority of the world’s researchers, and we look forward to changing that as we continue our battle against neglected tropical diseases (NTDs), malaria, and tuberculosis.

We enjoyed hosting our partners from the World Intellectual Property Organization (WIPO) at our Seattle offices in February to discuss WIPO Re:Search strategy and plans for 2019 and beyond.

WIPO Re:Search was recently featured in the WIPO and the Sustainable Development Goals report, which highlights the many ways that intellectual property (IP) is driving progress toward the Goals by enabling innovation and creativity.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

WIPO Re:Search Statistics

Click here for a list of WIPO Re:Search Members.
Click here for a list of WIPO Re:Search collaborations.
Click here to view the WIPO Re:Search Collaboration Pipeline.
Cornerstones of Collaboration

Eisai Shares Compounds to Aid in Leishmaniasis, Malaria, and HAT Drug Discovery

Leishmaniasis, malaria, and human African trypanosomiasis (HAT) are amongst the infectious diseases that disproportionately exact a heavy toll on people living in low- and middle-income countries (LMICs). Professor Fabrice Boyom, head of the Antimicrobial & Biocontrol Agents Unit (AmBcAU) at the University of Yaounde I, is working toward the discovery and development of novel drugs against HAT, leishmaniasis, and malaria by targeting the parasites’ critical metabolic pathways. To support Professor Boyom’s drug discovery efforts, Eisai Co., Ltd. will share dihydrofolate reductase (DHFR) inhibitors and potassium channel blockers.

MSD* Screens Candidates for Tuberculosis Drug Development

It is estimated that one quarter of the world’s population is infected with tuberculosis (TB). To deter the growing threat of multidrug-resistant TB, new treatments are needed to successfully reduce the global burden of this disease. Dr. Cynthia Dowd from The George Washington University has developed lead compounds with anti-tubercular activity, and could be promising candidates for TB drug development. In order to assist Dr. Dowd in target identification, MSD will be screening these compounds to determine their activity against a specific Mycobacterium tuberculosis target.

Dr. Greg Adam, a Principal Scientist in the Early Discovery and In Vitro Pharmacology division at MSD, will be leading the screening efforts to support the testing of Dr. Dowd’s anti-tubercular lead compounds.

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA
The World Intellectual Property Organization (WIPO) offers online tools and training sessions aimed at building human capacity in IP through the WIPO Academy. The Academy is a center of excellence for IP education and training for WIPO member states, particularly developing countries, least-developed countries (LDCs), and countries in transition. The Academy works closely with a number of government and academic partners, and its courses are offered in a range of languages.

**BVGH FundFinder Featured Awards**

**MMV 17th Call for Proposals**

Medicines for Malaria Venture (MMV) welcomes proposals in the following three areas necessary for the control and eradication of malaria:

- Compounds addressing the key priorities of the malaria eradication agenda
- Compounds having activity against asexual liver and/or blood stages
- Novel approaches for screening

For African malaria researchers in endemic regions, MMV has issued an additional African Call for Proposals.

**Amount:** Unspecified  
**Organization:** MMV  
**Deadline:** March 29, 2019  
**Eligibility:** Unspecified

**Additional Funding Opportunities**

- [ASTMH Annual Meeting Travel Awards](https://www.astmh.org/malaria-fundfinder/) – Deadline: March 20, 2019  
- [ASTMH Vulule-Odada Travel Awards for Kenyan Trainees](https://www.astmh.org/malaria-fundfinder/) – Deadline: March 20, 2019  
- [NIH Global Infectious Disease Research Training Program](https://nihglobalfunding.org/) – Deadline: Letter of Intent due June 25, 2019; Application due July 25, 2019  
- [Neglected Tropical Diseases Support Center: Operational Research on "Endgame" Challenges](https://www.astmh.org/malaria-fundfinder/) – Rolling Deadline
Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 13-16, 2019</td>
<td>European Congress of Clinical Microbiology and Infectious Diseases</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>April 14-17, 2019</td>
<td>World Vaccine Congress Washington</td>
<td>Washington, DC, USA</td>
</tr>
<tr>
<td>May 12-15, 2019</td>
<td>Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development</td>
<td>Dundee, UK</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada  | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.

Copyright © 2019 BVGH, All rights reserved.

Mailing address: 2101 4th Avenue, Suite 1950, Seattle, WA 98121